EGFR inhibitor Archives - Medical Conferences

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO 2022

5 August, 2022 15:19

Novel treatment option for KRAS wildtype pancreatic cancer

Presented By

Prof. Shukui Qin, Cancer Center of Jinling Hospital, China

Trial

Phase 3, NOTABLE

Conference

ASCO 2022

5 August, 2022 15:03

Consistent efficacy of osimertinib in Chinese and global population

Presented By

Dr Jie Wang, Beijing Cancer Hospital, China

Trial

Phase 3, ADAURA

Conference

ELCC 2022

25 May, 2022 12:43

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Presented By

Dr Chao Lyu, Beijing Cancer Hospital, China

Trial

Phase 2, NEOS

Conference

ELCC 2022

25 May, 2022 12:43

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

25 May, 2022 12:41

Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 2

Conference

ELCC 2022

25 May, 2022 12:40

Novel conjugate meets primary endpoint

Presented By

Dr Cristina Saura, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, TULIP

Conference

ESMO 2021

19 November, 2021 09:50

Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC

Presented By

Dr Jared Weiss, University of North Carolina at Chapel Hill, NC, USA

Trial

Phase 1/2, KRYSTAL-1

Conference

ESMO 2021

19 November, 2021 09:42

Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC

Presented By

Prof. Dominik Modest, Charité Universitätsmedizin Berlin, Germany

Trial

Phase 3, PANAMA

Conference

ASCO 2021

12 August, 2021 22:34

Amivantamab/lazertinib benefits patients with EGFR-mutated NCSLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea

Trial

CHRYSALIS, MARIPOSA

Journal

Physician's Weekly

Conference

ESMO Virtual Congress 2020

13 April, 2021 15:40

Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Conference

ESMO 2020

25 November, 2020 15:13

Cutaneous adverse events due to EGFR inhibitors

Presented By

Dr Pietro Sollena, University of the Sacred Heart in Rome, Italy

Conference

WCD 2019

26 August, 2019 20:44